Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ibcasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 19/20 | 0.71 |
| ▸ | AURKB known ✓ | Q96GD4 | 4/20 | 0.70 |
| ▸ | FLT1 known ✓ | P17948 | 1/20 | 0.60 |
| ▸ | FLT4 known ✓ | P35916 | 1/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 1/20 | 1.00 |
| ▸ | AURKA | O14965 | 6/20 | 0.70 |
| ▸ | MET | P08581 | 6/20 | 0.70 |
| ▸ | TEK | Q02763 | 6/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | LCK | P06239 | 3/20 | 0.61 |
| ▸ | CSF1R | P07333 | 1/20 | 0.60 |
| ▸ | BRAF | P15056 | 1/20 | 0.60 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ibcasertib SCHEMBL29883432 | 1.00 | PDGFRA (1.00) | PDGFRAKDRAURKAMETTEK | |
| Ibcasertib SCHEMBL29369945 | 1.00 | PDGFRA (1.00) | PDGFRAKDRAURKAMETTEK | |
| SCHEMBL3747657 | 0.92 | PDGFRA (0.85) | PDGFRAKDRAURKAMETTEK | |
| SCHEMBL3758008 | 0.91 | PDGFRA (0.83) | PDGFRAKDRAURKAMETTEK | |
| SCHEMBL3757940 | 0.90 | PDGFRA (0.81) | PDGFRAKDRAURKAMETTEK | |
| SCHEMBL3753779 | 0.89 | PDGFRA (0.81) | PDGFRAKDRAURKAMETTEK | |
| SCHEMBL3753804 | 0.89 | PDGFRA (0.80) | PDGFRAKDRAURKAMETTEK | |
| SCHEMBL7788968 | 0.87 | PDGFRA (0.76) | PDGFRAKDRAURKAMETTEK | |
| SCHEMBL2746823 | 0.87 | KDR (0.84) | PDGFRAKDRAURKAMETTEK | |
| SCHEMBL5774867 | 0.85 | KDR (0.83) | PDGFRAKDRAURKAMETTEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118178650-A | Application of naphthalimide derivative in preparation of hepatocellular carcinoma radiotherapy sensitization drugs | 中山大学附属第五医院 | 2024-06-14 | — | — | CN | claimed |
| CN-117377492-A | Pharmaceutical composition containing protein kinase inhibitor and medical application thereof | 深圳微芯生物科技股份有限公司 | 2024-01-09 | — | — | CN | claimed |
| US-20210213037-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-07-15 | — | — | US | claimed |
| EP-3752161-A1 | METHODS FOR TREATING FIBROSIS | Children's Hospital Medical Center (US) | 2020-12-23 | — | — | EP | claimed |
| CN-107868044-B | Non-solvation crystal and preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2020-10-16 | — | — | CN | claimed |
| WO-2019161000-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-08-22 | — | — | WO | claimed |
| CN-117377492-A | Pharmaceutical composition containing protein kinase inhibitor and medical application thereof | 深圳微芯生物科技股份有限公司 | 2024-01-09 | — | — | CN | disclosed |
| WO-2023130150-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-06 | — | — | WO | disclosed |
| US-20230117545-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PROTEIN KINASE INHIBITOR AND CHEMOTHERAPEUTIC DRUG AND USE THEREOF | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
| US-20220184055-A1 | CHIAURANIB FOR TREATMENT OF SMALL CELL LUNG CANCER | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2022-06-16 | — | — | US | disclosed |
| EP-3949966-A1 | CHIAURANIB FOR TREATMENT OF SMALL CELL LUNG CANCER | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021144360-A1 | SMALL MOLECULE CSF-1R INHIBITORS IN THERAPEUTIC AND COSMETIC USES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-07-22 | — | — | WO | disclosed |
| US-20210213037-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2021-07-15 | — | — | US | disclosed |
| WO-2019161000-A1 | METHODS FOR TREATING FIBROSIS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2019-08-22 | — | — | WO | disclosed |
| US-8211901-B2 | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2012-07-03 | — | — | US | disclosed |
| US-8211901-B2 | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2012-07-03 | — | — | US | disclosed |
| US-8211901-B2 | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2012-07-03 | — | — | US | disclosed |
| US-20100298358-A1 | Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298358-A1 | Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298358-A1 | Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors | SHENZHEN CHIPSCREEN BIOSCIENCES LTD. (CN) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117545-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PROTEIN KINASE INHIBITOR AND CHEMOTHERAPEUTIC DRUG AND USE THEREOF | PLK1, CHEK2, CHEK1 | KDR 523/4885AURKB 48/4885FLT1 1538/4885 |
| US-20100298358-A1 | Naphthamide Derivatives As Multi-Target Protein Kinase Inhibitors and Histone Deacetylase Inhibitors | HDAC1, HDAC2, HDAC5 | KDR 2729/4885AURKB 586/4885FLT1 3724/4885 |
| US-20220184055-A1 | CHIAURANIB FOR TREATMENT OF SMALL CELL LUNG CANCER | CHIA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DCK | KDR 218/4885AURKB 9/4885FLT1 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.